Drugs / Neoantigen DNA vaccine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03199040 | Jul 2019 → Nov 2022 | triple-negative breast carcinoma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03532217 | Sep 2018 → Apr 2022 | metastatic prostate carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04397003 | Mar 2022 → Sep 2027 expected | small cell lung carcinoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03598816 | Aug 2020 → Dec 2022 | renal cell carcinoma | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03914872 | — | cancer | Washington University School of Medicine | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen DNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03199040 ↗ |
| Modality | Vaccine | “Neoantigen DNA vaccine” NCT03199040 ↗ |
| Route | Intramuscular | “The vaccine will be administered starting approximately week 21 by intramuscular injection” NCT03532217 ↗ |